Kohei Kume, PhD
Research ScientistDownloadHi-Res Photo
Cards
Appointments
Medical Oncology and Hematology
Primary
Contact Info
About
Copy Link
Titles
Research Scientist
Biography
Dr. Kohei Kume completed his PhD at Iwate University (Morioka, Japan) in 2011 with mentorship from Yasushi Saitoh, PhD. After a postdoctoral training at Iwate Medical University with mentorship from Satoshi S. Nishizuka MD, PhD, he joined Dr. Markus Müschen’s laboratory in 2017 at the Beckman Research Institute of the City of Hope. He is currently a Research Scientist in Dr. Müschen’s laboratory at Yale University, and studies the mechanisms and functional significance of autonomous Ca2+ oscillations in oncogenic signaling of multiple B-cell malignancies.
Last Updated on September 24, 2024.
Appointments
Medical Oncology and Hematology
Research ScientistPrimary
Other Departments & Organizations
- Center of Molecular and Cellular Oncology
- Hematology
- Medical Oncology and Hematology
- Müschen Lab
Education & Training
- Associate Research Scientist
- Yale University
- Staff Scientist
- City of Hope
- Associate Instructor
- Iwate Medical University
- Postdoctoral Fellow
- Iwate Medical University
- PhD
- Iwate University, Bioresources Sciences (2011)
Research
Copy Link
Overview
Medical Research Interests
Cell Size; Drug Resistance; Leukemia; Lipid Metabolism; Lymphoma; Oncogenes; Optogenetics; Protein Array Analysis; Proteogenomics
Public Health Interests
Biomarkers; Cancer
ORCID
0000-0003-2856-5970- View Lab Website
Lab Website
Research at a Glance
Yale Co-Authors
Frequent collaborators of Kohei Kume's published research.
Publications Timeline
A big-picture view of Kohei Kume's research output by year.
Research Interests
Research topics Kohei Kume is interested in exploring.
Markus Müschen, MD, PhD
Kadriye Nehir Cosgun, PhD
Mark Robinson, PhD
Jaewoong Lee, PhD
Lars Klemm
Etienne Leveille, MD, PhD
27Publications
617Citations
Protein Array Analysis
Drug Resistance
Publications
2026
Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia
Lee J, Sun R, Kume K, Robinson M, Cheng Z, Cosgun K, Ma N, Hurtz C, Geng H, Luger S, Litzow M, Paietta E, Chen J, Vaidehi N, Müschen M. Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia. Science Signaling 2026, 19: eadw5054-eadw5054. PMID: 41666265, PMCID: PMC12924454, DOI: 10.1126/scisignal.adw5054.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsOncogenic tyrosine kinase signalingTyrosine kinase signalingPatient-derived xenograftsKinase signalingAcute leukemiaNatural killerInterleukin-2Tyrosine kinaseLeukemia cellsLeukemia-initiating capacityActivation of tyrosine kinasesGlobal phosphoproteome analysisOncogenic tyrosine kinasesPhosphatase activityInteractome analysisModels of acute leukemiaAntibody-drug conjugatesAcute leukemia cellsPhosphoproteomic analysisClonal fitnessRefractory leukemiaTransplant recipientsInhibitory phosphatasesMyeloid leukemiaT cellsTargeting β-catenin degradation with GSK3β inhibitors induces cell death in acute lymphoblastic leukemia
Cosgun K, Jumaa H, Robinson M, Cheng Z, Oulghazi S, Kume K, Fonseca Arce D, Agadzhanian N, Kistner K, Leveille E, Drivet E, Yu F, Qian Z, Song J, Chan W, Xu L, Xiao G, Taketo M, Kothari S, Davids M, Schjerven H, Jellusova J, Müschen M. Targeting β-catenin degradation with GSK3β inhibitors induces cell death in acute lymphoblastic leukemia. Nature Cancer 2026, 7: 150-168. PMID: 41507538, PMCID: PMC12858398, DOI: 10.1038/s43018-025-01093-z.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsProtein degradationCell deathProtein degradation machineryAcute lymphoblastic leukemiaGlycogen synthase kinase 3bB-ALLXenograft model in vivoDegradation machineryCRISPR screensMyc repressionProteasomal degradationHuman B-ALLLymphoblastic leukemiaPatient-derived xenograft models in vivoRefractory B-cell malignanciesB-cateninB-cell acute lymphoblastic leukemiaAcute cell deathWnt signalingGSK3BB-cell malignanciesMechanistic targetProteinMYCModel in vivo
2024
Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit
Kume K, Iida M, Iwaya T, Yashima-Abo A, Koizumi Y, Endo A, Wade K, Hiraki H, Calvert V, Wulfkuhle J, Espina V, Siwak D, Lu Y, Takemoto K, Suzuki Y, Sasaki Y, Tokino T, Petricoin E, Liotta L, Mills G, Nishizuka S. Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit. Molecular & Cellular Proteomics 2024, 23: 100870. PMID: 39461475, PMCID: PMC11621936, DOI: 10.1016/j.mcpro.2024.100870.Peer-Reviewed Original ResearchCitationsAltmetricConceptsDNA-damaging drugsTotal lymphocyte countCell linesResistance to DNA damaging drugsPD-L1Adjuvant chemotherapyProtein dynamicsProtein-level regulationSurvival benefitCopy number lossExpression time courseGastric cancerRelapse-free survival rateGastric cancer cellsHost immunityAssociated with prolonged survivalIncreased STAT1 phosphorylationResistance to other drugsGlobal protein dynamicsImmune checkpoint blockadePD-L1 positivityPD-L1 expressionAdvanced gastric cancerExpression of STAT1Molecular targeted drugs
2022
Helicobacter pylori modulated host immunity in gastric cancer patients with S-1 adjuvant chemotherapy.
Koizumi Y, Ahmad S, Ikeda M, Yashima-Abo A, Espina G, Sugimoto R, Sugai T, Iwaya T, Tamura G, Koeda K, Liotta LA, Takahashi F, Nishizuka SS, Northern Japan Gastric Cancer Study Consortium .. Helicobacter pylori modulated host immunity in gastric cancer patients with S-1 adjuvant chemotherapy. J Natl Cancer Inst 2022 PMID: 35437596, DOI: 10.1093/jnci/djac085.Peer-Reviewed Original ResearchSYK and ZAP70 kinases in autoimmunity and lymphoid malignancies
Leveille E, Chan LN, Mirza AS, Kume K, Müschen M. SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies. Cellular Signalling 2022, 94: 110331. PMID: 35398488, DOI: 10.1016/j.cellsig.2022.110331.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsChronic lymphocytic leukemiaB-cell malignanciesT cell receptorB cell receptorB-cell chronic lymphocytic leukemiaPathological B-cellsPoor clinical outcomeAcute lymphoblastic leukemiaExpression of SykT lymphocyte developmentClinical outcomesAggressive diseaseActivation of NFATAutoimmune diseasesLymphoblastic leukemiaT lymphocytesLymphocytic leukemiaCell lymphomaLymphoid malignanciesB cellsPI3K-pathwayOncogenic driversMalignancyNegative selectionPremalignant cells
2021
Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer
Sadras T, Martin M, Kume K, Robinson ME, Saravanakumar S, Lenz G, Chen Z, Song JY, Siddiqi T, Oksa L, Knapp AM, Cutler J, Cosgun KN, Klemm L, Ecker V, Winchester J, Ghergus D, Soulas-Sprauel P, Kiefer F, Heisterkamp N, Pandey A, Ngo V, Wang L, Jumaa H, Buchner M, Ruland J, Chan WC, Meffre E, Martin T, Müschen M. Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Molecular Cell 2021, 81: 2094-2111.e9. PMID: 33878293, PMCID: PMC8239336, DOI: 10.1016/j.molcel.2021.03.043.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntigens, CD19AutoimmunityB-LymphocytesCalciumCell DifferentiationCell Transformation, NeoplasticEnzyme ActivationHumansImmune ToleranceLymphoma, B-CellMiceModels, GeneticNeoplasm ProteinsNeoplasmsNFATC Transcription FactorsPhosphatidylinositol 3-KinasesProtein BindingReceptors, Antigen, B-CellSignal TransductionSyk KinaseZAP-70 Protein-Tyrosine KinasePON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis
Pan L, Hong C, Chan LN, Xiao G, Malvi P, Robinson ME, Geng H, Reddy ST, Lee J, Khairnar V, Cosgun KN, Xu L, Kume K, Sadras T, Wang S, Wajapeyee N, Müschen M. PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2016553118. PMID: 33531346, PMCID: PMC7896313, DOI: 10.1073/pnas.2016553118.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTransplant recipient miceDNA double-strand breaksNormal B cell developmentDouble-strand breaksB cell developmentGenetic deletionB cellsLymphoid transcription factorsGlucose transporter GLUT1Gatekeeper functionGlucose uptakeRecipient miceTranscription factorsSomatic recombinationSynthetic lethalityB-cell acute lymphoblastic leukemiaCell developmentMetabolic gatekeeperRefractory B-ALLDeficient murineCell acute lymphoblastic leukemiaPoor clinical outcomeCell typesAcute lymphoblastic leukemiaGlucose transport
2020
IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells
Lee J, Robinson ME, Ma N, Artadji D, Ahmed MA, Xiao G, Sadras T, Deb G, Winchester J, Cosgun KN, Geng H, Chan LN, Kume K, Miettinen TP, Zhang Y, Nix MA, Klemm L, Chen CW, Chen J, Khairnar V, Wiita AP, Thomas-Tikhonenko A, Farzan M, Jung JU, Weinstock DM, Manalis SR, Diamond MS, Vaidehi N, Müschen M. IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. Nature 2020, 588: 491-497. PMID: 33149299, PMCID: PMC8087162, DOI: 10.1038/s41586-020-2884-6.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntigens, CD19B-LymphocytesCell Transformation, NeoplasticFemaleGerminal CenterHumansIntegrinsMembrane MicrodomainsMembrane ProteinsMiceMice, Inbred C57BLMice, Inbred NODModels, MolecularPhosphatidylinositol 3-KinasesPhosphatidylinositol PhosphatesPhosphorylationReceptors, Antigen, B-CellRNA-Binding ProteinsSignal TransductionConceptsPI3KCell leukemiaAntiviral effector functionsAntigen-specific antibodiesInterferon-induced transmembrane proteinsIFITM3 functionDevelopment of leukemiaCell surfacePoor outcomeOncogenic PI3KClinical cohortEffector functionsGerminal centersMouse modelB cellsExpression of IFITM3Malignant transformationAccumulation of PIP3PI3K signalsCell receptorNormal numbersLeukemiaDefective expressionEndosomal proteinIFITM3Signalling input from divergent pathways subverts B cell transformation
Chan LN, Murakami MA, Robinson ME, Caeser R, Sadras T, Lee J, Cosgun KN, Kume K, Khairnar V, Xiao G, Ahmed MA, Aghania E, Deb G, Hurtz C, Shojaee S, Hong C, Pölönen P, Nix MA, Chen Z, Chen CW, Chen J, Vogt A, Heinäniemi M, Lohi O, Wiita AP, Izraeli S, Geng H, Weinstock DM, Müschen M. Signalling input from divergent pathways subverts B cell transformation. Nature 2020, 583: 845-851. PMID: 32699415, PMCID: PMC7394729, DOI: 10.1038/s41586-020-2513-4.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsB-LymphocytesCell Line, TumorCell Transformation, NeoplasticEnzyme ActivationExtracellular Signal-Regulated MAP KinasesFemaleHumansLeukemia, B-CellMiceProtein Tyrosine Phosphatase, Non-Receptor Type 6Proto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-mycSignal TransductionSTAT5 Transcription FactorConceptsPre-B cell receptorPrincipal oncogenic driverDivergent pathwaysSignal transduction proteinsPro-B cell stageSingle-cell mutationTranscription factor MYCOncogenic driversDivergent signaling pathwaysSingle oncogenic pathwayCentral oncogenic driverMore mature cellsGenetic reactivationTranscriptional programsB-cell transformationProtein kinasePathway componentsERK activationIndividual mutationsOncogenic STAT5Signaling pathwaysCell transformationCytokine receptorsGenetic lesionsDivergent circuits
2019
RPPAs for Cell Subpopulation Analysis
Kume K, Nishizuka SS. RPPAs for Cell Subpopulation Analysis. Advances In Experimental Medicine And Biology 2019, 1188: 227-237. PMID: 31820391, DOI: 10.1007/978-981-32-9755-5_12.ChaptersMeSH Keywords and ConceptsConceptsDrug-tolerant persistersStem cell-associated proteinsReverse phase protein arrayTolerant cell linesCell linesPhase protein arrayDifferent cell typesCell-associated proteinsGastric cancer cell linesCell biologyProteomic profilingProteomic profilesTolerant linesCellular heterogeneityClonal populationsCancer biologyPI3KCell typesCancer cell linesProtein arraysStem cellsIndividual subpopulationsProliferative conditionsBiologyProtein
Academic Achievements & Community Involvement
Copy Link
Honors
honor Nominated for full membership in Sigma Xi
09/09/2025National AwardSigma XiDetailsUnited Stateshonor ASH Abstract Achievement Award
10/23/2023, 11/12/2021, 11/29/2019, 10/29/2018, 10/31/2017National AwardAmerican Society of Hematologyhonor Research Grant from The Japan Prize Foundation
04/01/2012National AwardThe Japan Prize FoundationDetailsJapanhonor Sasakawa Scientific Research Grant
04/01/2009National AwardThe Japan Science SocietyDetailsJapan
News
Copy Link
News
- February 10, 2026
Yale Study Identifies a New Class of Drug Targets for Aggressive Leukemia
- January 08, 2026
Yale-Led Study Identifies a New Target for Treating Acute Leukemia
- February 26, 2025
Celebrating Yale Cancer Center Faculty, Research Scientists
- July 24, 2024
Yale Department of Internal Medicine Faculty Promotions and Appointments (July 2024)
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Mailing Address
Müschen Lab
300 George Street
New Haven, CT 06511
United States